Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cellular Immunotherapy to Target CD3 and EGFR for Oncology by Transtarget for Glioblastoma Multiforme (GBM): Likelihood of Approval
Cellular Immunotherapy to Target CD3 and EGFR for Oncology is under clinical development by Transtarget and currently in Phase I...
Cellular Immunotherapy to Target CD3 and EGFR for Oncology by Transtarget for Gliosarcoma: Likelihood of Approval
Cellular Immunotherapy to Target CD3 and EGFR for Oncology is under clinical development by Transtarget and currently in Phase I...
Cellular Immunotherapy to Target CD3 and EGFR for Oncology by Transtarget for Metastatic Colorectal Cancer: Likelihood of Approval
Cellular Immunotherapy to Target CD3 and EGFR for Oncology is under clinical development by Transtarget and currently in Phase I...